小细胞肺癌血清NSE、CIC、CEA检测的临床意义  

THE CLINIC VALUE OF SERUM NSE,CIC AND CEA IN SMALL CELL LUNG CANCER

作　　者：韩葆惠 高育瑶[1] 贾友明[1] 周敏[1] 

机构地区：[1]上海医科大学中山医院肺科

出　　处：《上海医科大学学报》1994年第3期187-190,共4页Journal of Fudan University(Medical Science)

摘　　要：对４８名肺癌病人治疗前的神经烯醇化酶（ＮＳＥ）、循环免疫复合物（ＣＩＣ）、癌胚抗原（ＣＥＡ）分别进行了测定，并对部分小细胞肺癌（ＳＣＬＣ）进行了治疗前后ＮＳＥ的动态观察。结果显示：ＮＳＥ对ＳＣＬＣ病人阳性诊断率为６６．７％，其中广泛期达８０％，而ＣＥＡ和ＣＩＣ对ＳＣＬＣ病人分别为１１．１％和４６．６％。ＳＣＬＣ与非小细胞肺癌（ＮＳＣＬＣ）、良性肺部疾病（ＢＰＤ）相比较，其血清ＮＳＥ显著升高（Ｐ＜０．０５）。对小细胞肺癌病人连续观察：化疗完全缓解及部分缓解者血清ＮＳＥ明显下降，而病情恶化或出现转移时，血清ＮＳＥ持续升高。血清ＮＳＥ作为诊断小细胞肺癌、预测疗效、判断复发具有一定的临床意义。Serum neuron specific enolase(NSE),carcinoembryonic antigen(CEA),circulating immune complexes(CIC)were measured in 48 patients pretherapy.NSE levels in the small cell lung cancer(SCLC)patients were continually measured,both pretherapy and postherapy.Results showed that the rate of the pesitive diagnostic rate of NSE in SCLC was 66.7%;extent disease 80%.Elevated concentrations of serum CEA and CIC were found in 11.1% and 66.6% of SCLC patients,NSE was also significantly elevated compared with that in cases of non SCLC and benign pulmonary diseases(P<0.05).Continual observations after initiation of tlierapy,serum-NSE declined inarkedly in patients with complete response and partial response.Wherease,serum-NSE remained continuously elevated.Thus,serum-NSE is a valuable tumor marker for SCLC diagnosis,monitoring the response of therapy and estimating relapse.

关 键 词：酶 癌胚抗原 免疫复合物 肺肿瘤 

分 类 号：R734.204[医药卫生—肿瘤]